Product image of Mounjaro Kwikpen (Tirzepatide) supplied by GNH India

Mounjaro Kwikpen

Active Ingredient:
Tirzepatide
Origin:
EU

Mounjaro Kwikpen (Tirzepatide)

tirzepatide, the active ingredient in Mounjaro Kwikpen, is a GIP/GLP‑1 receptor agonist presented as an injectable solution (prefilled pen) for subcutaneous use. It is indicated for the treatment of type 2 diabetes mellitus in adult patients, helping improve glycaemic control and supporting weight management.

GNH India supplies Mounjaro Kwikpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for injectable products, ensuring product integrity during transport and storage.

Manufacturer / TM Owner

Eli Lilly Nederland B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mounjaro Kwikpen (tirzepatide) is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder.

  • Type 2 diabetes mellitus: improves blood glucose levels and supports weight reduction.
  • Adjunct to diet and exercise: enhances insulin secretion when combined with lifestyle measures.
  • Combination with other antidiabetic agents: provides additional HbA1c lowering when added to existing therapy.

How It Works

  • Tirzepatide activates both glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors. Dual receptor activation increases insulin secretion in a glucose‑dependent manner, suppresses glucagon release, and slows gastric emptying, collectively leading to better glycaemic control and modest weight loss.

Side Effects

Common Side Effects

  • Nausea: mild to moderate, often transient.
  • Vomiting: may accompany nausea.
  • Diarrhea: usually self‑limiting.
  • Constipation: occasional.
  • Decreased appetite: reduced food intake.
  • Abdominal pain: mild discomfort.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring immediate medical attention.
  • Severe allergic reactions: anaphylaxis or angioedema.
  • Gallbladder disease: cholelithiasis or cholecystitis.
  • Severe hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Renal impairment: acute kidney injury in susceptible individuals.
  • Thyroid C‑cell tumors: observed in rodent studies, caution in at‑risk patients.

Precautions & Warnings

Before initiating therapy, consider the following precautions:

  • Dose titration: start low and increase gradually as directed by the prescriber.
  • Renal function: assess baseline renal status and monitor periodically.
  • Gastrointestinal disorders: monitor for persistent nausea, vomiting, or diarrhea.
  • Pancreatitis risk: discontinue if signs of pancreatitis develop.
  • Thyroid C‑cell tumor risk: avoid in patients with a history of medullary thyroid carcinoma or MEN2.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Tirzepatide may interact with other medicines. Review the following:

Major Interactions (Avoid)

  • Insulin or sulfonylureas: increased risk of severe hypoglycaemia; dose adjustment required.
  • Medications that delay gastric emptying: may exacerbate gastrointestinal side effects.

Moderate Interactions (Monitor Closely)

  • Warfarin: monitor INR values regularly.
  • Oral contraceptives: possible reduced absorption, consider alternative contraception.
  • ACE inhibitors or ARBs: monitor renal function and blood pressure.
  • Other GLP‑1 receptor agonists: avoid concurrent use due to overlapping mechanisms.

Frequently Asked Questions

Mounjaro Kwikpen contains tirzepatide and is prescribed for adults with type 2 diabetes mellitus to improve blood glucose control and assist with weight management when used alongside diet and exercise.

Tirzepatide simultaneously activates GIP and GLP‑1 receptors, which enhances insulin secretion in response to glucose, suppresses glucagon release, and slows gastric emptying. These actions together lower blood sugar levels and promote modest weight loss.

The dose of tirzepatide is individualized by the prescribing healthcare professional. The prescriber determines the starting dose, titration schedule, and maintenance dose based on the patient’s clinical condition and response.

The safety of tirzepatide in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mounjaro Kwikpen (tirzepatide) is a dual GIP/GLP‑1 receptor agonist, offering greater HbA1c reduction and weight loss compared with many single‑target GLP‑1 analogues. Its efficacy profile may be advantageous for patients needing additional glycaemic control, though individual response and tolerability vary.

Mounjaro Kwikpen should be stored in a refrigerator at 2‑8 °C, protected from light. Do not freeze or shake the pen. If needed, it may be kept at room temperature (up to 30 °C) for a maximum of 14 days, after which any unused medication must be discarded.

The medication is supplied as a prefilled pen for subcutaneous injection. Patients or caregivers inject the prescribed dose into the abdomen, thigh, or upper arm, rotating sites with each injection to reduce local irritation.

Serious risks include pancreatitis, severe allergic reactions (anaphylaxis), gallbladder disease, and potential thyroid C‑cell tumors observed in animal studies. Prompt medical attention is required if symptoms such as persistent abdominal pain, swelling, or difficulty breathing occur.

Mounjaro Kwikpen is contraindicated in individuals with a known hypersensitivity to tirzepatide or any excipients, and in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. It should also be used with caution in those with severe gastrointestinal disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tirzepatide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT